bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Authors: Dawson Mark A. , Borthakur Gautam , Huntly Brian J.P. , Karadimitris Anastasios , Alegre Adrian , Chaidos Aristeidis , Vogl Dan T. , Pollyea Daniel A. , Davies Faith E. , Morgan Gareth J. , Glass Jacob L. , Kamdar Manali , Mateos Maria-Victoria , Tovar Natalia , Yeh Paul , Delgado Regina García , Basheer Faisal , Marando Ludovica , Gallipoli Paolo , Wyce Anastasia , Krishnatry Anu Shilpa , Barbash Olena , Bakirtzi Evi , Ferron-Brady Geraldine , Karpinich Natalie O. , McCabe Michael T. , Foley Shawn W. , Horner Thierry , Dhar Arindam , Kremer Brandon E. , Dickinson Michael
Published: April 2023

AbstractPurpose:
Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematological malignancies (NCT01943851).
Patients and Methods:
Part 1 (dose escalation) determined the recommended Phase 2 dose (RP2D) of molibresib in patients with acute myeloid leukemia (AML), Non–Hodgkin lymphoma (NHL), or multiple myeloma. Part 2 (dose expansion) investigated the safety and efficacy of molibresib at the RP2D in patients with relapsed/refractory myelodysplastic syndrome (MDS; as well as AML evolved from antecedent MDS) or cutaneous T-cell lymphoma (CTCL). The primary endpoint in Part 1 was safety and the primary endpoint in Part 2 was objective response rate (ORR).
Results:
There were 111 patients enrolled (87 in Part 1, 24 in Part 2). Molibresib RP2Ds of 75 mg daily (for MDS) and 60 mg daily (for CTCL) were selected. Most common Grade 3+ adverse events included thrombocytopenia (37%), anemia (15%), and febrile neutropenia (15%). Six patients achieved complete responses [3 in Part 1 (2 AML, 1 NHL), 3 in Part 2 (MDS)], and 7 patients achieved partial responses [6 in Part 1 (4 AML, 2 NHL), 1 in Part 2 (MDS)]. The ORRs for Part 1, Part 2, and the total study population were 10% [95% confidence interval (CI), 4.8–18.7], 25% (95% CI, 7.3–52.4), and 13% (95% CI, 6.9–20.6), respectively.
Conclusions:
While antitumor activity was observed with molibresib, use was limited by gastrointestinal and thrombocytopenia toxicities. Investigations of molibresib as part of combination regimens may be warranted.
Data from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Authors: Wei Fang , Su Yuling , Quan Yibo , Li Xiaojia , Zou Qi , Zhang Liuxi , Li Shu , Jiang Mengmeng , Lin Guohuan , Liang Ping , He Jie , Xie Keping
Published: April 2023

AbstractPurpose:
Pancreatic ductal adenocarcinoma (PDA) resists immunotherapy of adoptive cell transfer (ACT) and immune checkpoint inhibitors. Understanding the mechanisms underlying this resistance will improve PDA immunotherapy. This study investigated therapeutic effects and underlying mechanisms of anticoagulants on immunotherapy in PDA.
Experimental Design:
The antitumor activity of immunotherapy was evaluated in mouse models of desert, excluded, and inflamed tumors. The underlying mechanisms were investigated by analyzing immune cell infiltration by immunofluorescence imaging and tumor microcirculation by interstitial fluid pressure and coagulation status measurement.
Results:
Combined use of heparin and ACT inhibited tumor growth and metastasis, whereas neither heparin nor ACT had any therapeutic effect. The combination of heparin and ACT significantly increased the intratumor infiltration of CD8+ T cells and M1 macrophages and reduced the infiltration of immunosuppressive M2 macrophages and FOXP3+/CD4+ regulatory T cells (Treg). Assessments of tumor microenvironment revealed that heparin promoted tumor vascular regression and normalized the remaining blood vessels, facilitating the extravasation and perivascular accumulation of activated CD8+ T cells in tumors. Mechanistically, tumor microvessel hemodynamic properties were significantly improved by heparin, which is consistent with its inhibitory effects on tumor angiogenesis. Similarly, the combination of heparin and anti-PD1 also produced a pronounced antitumor activity, whereas neither heparin nor anti-PD1 treatment had appreciable antitumor activity.
Conclusions:
Combined treatment of heparin and ACT or anti-PD1 produced synergistic antitumor effects, which were at least in part through tumor vascular normalization, hence increased antitumor T-cell responses due to reduced Treg infiltration and increased M1 macrophage polarization. This synergistic combination therapy warrants clinical evaluation.
Supplementary Fig. S2 from Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway
Authors: Co Ngai Na , Tsang Wing Pui , Wong Timothy W.L. , Cheung Hoi Hung , Tsang Tsun Yee , Kong Siu Kai , Kwok Tim Tak
Published: April 2023

Supplementary Fig. S2 from Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway
Supplementary Fig. S1 from Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway
Authors: Co Ngai Na , Tsang Wing Pui , Wong Timothy W.L. , Cheung Hoi Hung , Tsang Tsun Yee , Kong Siu Kai , Kwok Tim Tak
Published: April 2023

Supplementary Fig. S1 from Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway
Supplementary Fig. from Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition
Authors: Yagi Hiroshi , Yotsumoto Fusanori , Miyamoto Shingo
Published: April 2023

Supplementary Fig. from Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition
Supplementary Fig. from Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines
Authors: Hussain Azhar R. , Ahmed Maqbool , Al-Jomah Naif A. , Khan Asma S. , Manogaran Pulicat , Sultana Mehar , Abubaker Jehad , Platanias Leonidas C. , Al-Kuraya Khawla S. , Uddin Shahab
Published: April 2023

Supplementary Fig. from Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines
Supplementary Fig. S4 from Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
Authors: Parsels Leslie A. , Morgan Meredith A. , Tanska Daria M. , Parsels Joshua D. , Palmer Brian D. , Booth R. John , Denny William A. , Canman Christine E. , Kraker Alan J. , Lawrence Theodore S. , Maybaum Jonathan
Published: April 2023

Supplementary Fig. S4 from Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
Supplementary Fig. S3 from Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
Authors: Parsels Leslie A. , Morgan Meredith A. , Tanska Daria M. , Parsels Joshua D. , Palmer Brian D. , Booth R. John , Denny William A. , Canman Christine E. , Kraker Alan J. , Lawrence Theodore S. , Maybaum Jonathan
Published: April 2023

Supplementary Fig. S3 from Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
Supplementary Fig. S4 from Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer
Authors: Afshar Sepideh , Asai Tsuneaki , Morrison Sherie L.
Published: April 2023

Supplementary Fig. S4 from Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer
Supplementary Fig. S2 from Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer
Authors: Afshar Sepideh , Asai Tsuneaki , Morrison Sherie L.
Published: April 2023

Supplementary Fig. S2 from Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer
Supplementary Table S1 from Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms
Authors: Chen Zhong , Ricker Justin L. , Malhotra Pramit S. , Nottingham Liesl , Bagain Lorena , Lee Tin Lap , Yeh Ning T. , Van Waes Carter
Published: April 2023

Supplementary Table S1 from Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms
Supplementary Figure Legends from Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin
Authors: Peklak-Scott Christina , Smitherman Pamela K. , Townsend Alan J. , Morrow Charles S.
Published: April 2023

Supplementary Figure Legends from Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin
Supplementary Data from Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant
Authors: Wang Yanping , Wang Xiang-Yang , Subjeck John R. , Kim Hyung L.
Published: April 2023

Supplementary Data from Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant
Supplementary Fig. S1 from A role for macroautophagy in protection against 4-hydroxytamoxifen–induced cell death and the development of antiestrogen resistance
Authors: Samaddar Julia S. , Gaddy Virgil T. , Duplantier Jennifer , Thandavan Sudharsan Periyasamy , Shah Manish , Smith Marlena J. , Browning Darren , Rawson Jim , Smith Sylvia B. , Barrett John T. , Schoenlein Patricia V.
Published: April 2023

Supplementary Fig. S1 from A role for macroautophagy in protection against 4-hydroxytamoxifen–induced cell death and the development of antiestrogen resistance
Supplementary Figure 5 from Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo
Authors: Jantscheff Peter , Schlesinger Martin , Fritzsche Juliane , Taylor Lenka A. , Graeser Ralph , Kirfel Gregor , Fürst Dieter O. , Massing Ulrich , Bendas Gerd
Published: April 2023

Supplementary Figure 5 from Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo
Supplementary Table S2 from A genomic approach to identify molecular pathways associated with chemotherapy resistance
Authors: Riedel Richard F. , Porrello Alessandro , Pontzer Emily , Chenette Emily J. , Hsu David S. , Balakumaran Bala , Potti Anil , Nevins Joseph , Febbo Phillip G.
Published: April 2023

Note: Supplementary Table S1 was retracted by the authors on March 29, 2012 and has been removed from the site.
Supplementary Fig. S1 from Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments
Authors: Gao Jie , Kou Geng , Chen Huaiwen , Wang Hao , Li Bohua , Lu Ying , Zhang Dapeng , Wang Shuhui , Hou Sheng , Qian Weizhu , Dai Jianxin , Zhao Jian , Zhong Yanqiang , Guo Yajun
Published: April 2023

Supplementary Fig. S1 from Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments
Supplementary Fig. S3 from Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Authors: Bataller Marc , Méndez Carmen , Salas José A. , Portugal José
Published: April 2023

Supplementary Fig. S3 from Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Supplementary Fig. S3 from Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-α]quinoline in colon cancer cells depending on their p53 status
Authors: Sedic Mirela , Poznic Miroslav , Gehrig Peter , Scott Mike , Schlapbach Ralph , Hranjec Marijana , Karminski-Zamola Grace , Pavelic Kresimir , Pavelic Sandra Kraljevic
Published: April 2023

Supplementary Fig. S3 from Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-α]quinoline in colon cancer cells depending on their p53 status
Supplementary Fig. S3 from The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis
Authors: Raja Shruti M. , Chen Shuzhen , Yue Ping , Acker Timothy M. , Lefkove Benjamin , Arbiser Jack L. , Khuri Fadlo R. , Sun Shi-Yong
Published: April 2023

Supplementary Fig. S3 from The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis
Supplementary Table S2 from EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance
Authors: Zhang Yuexing , Linn Douglas , Liu Zhenqiu , Melamed Jonathan , Tavora Fabio , Young Charles Y. , Burger Angelika M. , Hamburger Anne W.
Published: April 2023

Supplementary Table S2 from EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance
Supplementary Table S1 from EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance
Authors: Zhang Yuexing , Linn Douglas , Liu Zhenqiu , Melamed Jonathan , Tavora Fabio , Young Charles Y. , Burger Angelika M. , Hamburger Anne W.
Published: April 2023

Supplementary Table S1 from EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance
Supplementary Fig. S1 from Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
Authors: Miyanaga Akihiko , Gemma Akihiko , Noro Rintaro , Kataoka Kiyoko , Matsuda Kuniko , Nara Michiya , Okano Tetsuya , Seike Masahiro , Yoshimura Akinobu , Kawakami Akiko , Uesaka Haruka , Nakae Hiroki , Kudoh Shoji
Published: April 2023

Supplementary Fig. S1 from Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Authors: Fournel Marielle , Bonfils Claire , Hou Yu , Yan Pu Theresa , Trachy-Bourget Marie-Claude , Kalita Ann , Liu Jianhong , Lu Ai-Hua , Zhou Nancy Z. , Robert Marie-France , Gillespie Jeffrey , Wang James J. , Ste-Croix Hélène , Rahil Jubrail , Lefebvre Sylvain , Moradei Oscar , Delorme Daniel , MacLeod A. Robert , Besterman Jeffrey M. , Li Zuomei
Published: April 2023

Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Supplementary Table S1 from Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Authors: Song Dongweon , Chaerkady Raghothama , Tan Aik Choon , García-García Elena , Nalli Anuradha , Suárez-Gauthier Ana , López-Ríos Fernando , Zhang Xian Feng , Solomon Anna , Tong Jeffrey , Read Margaret , Fritz Christian , Jimeno Antonio , Pandey Akhilesh , Hidalgo Manuel
Published: April 2023

Supplementary Table S1 from Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Supplementary Fig. S1 from Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer
Authors: Duan Zhenfeng , Weinstein Edward J. , Ji Diana , Ames Rachel Y. , Choy Edwin , Mankin Henry , Hornicek Francis J.
Published: April 2023

Supplementary Fig. S1 from Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer
Supplementary Table 2 from Global microRNA Analysis of the NCI-60 Cancer Cell Panel
Authors: Søkilde Rolf , Kaczkowski Bogumil , Podolska Agnieszka , Cirera Susanna , Gorodkin Jan , Møller Søren , Litman Thomas
Published: April 2023

Supplementary Table 2 from Global microRNA Analysis of the NCI-60 Cancer Cell Panel
Supplementary Table S2 from NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells
Authors: John-Aryankalayil Molykutty , Palayoor Sanjeewani T. , Cerna David , Falduto Michael T. , Magnuson Scott R. , Coleman C. Norman
Published: April 2023

Supplementary Table S2 from NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells
Supplementary Figure 1 from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Authors: Hou Xiaonan , Huang Fei , Carboni Joan M. , Flatten Karen , Asmann Yan W. , Ten Eyck Cynthia , Nakanishi Takeo , Tibodeau Jennifer D. , Ross Douglas D. , Gottardis Marco M. , Erlichman Charles , Kaufmann Scott H. , Haluska Paul
Published: April 2023

Supplementary Figure 1 from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Supplementary Fig. S2 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Authors: Ding Yan , Boguslawski Elissa A. , Berghuis Bree D. , Young John J. , Zhang Zhongfa , Hardy Kim , Furge Kyle , Kort Eric , Frankel Arthur E. , Hay Rick V. , Resau James H. , Duesbery Nicholas S.
Published: April 2023

Supplementary Fig. S2 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Supplementary Table S1 from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Authors: Orth James D. , Tang Yangzhong , Shi Jade , Loy Clement T. , Amendt Christiane , Wilm Claudia , Zenke Frank T. , Mitchison Timothy J.
Published: April 2023

Supplementary Table S1 from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Supplementary Methods from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Authors: Orth James D. , Tang Yangzhong , Shi Jade , Loy Clement T. , Amendt Christiane , Wilm Claudia , Zenke Frank T. , Mitchison Timothy J.
Published: April 2023

Supplementary Methods from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Supplementary Fig. from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Authors: Orth James D. , Tang Yangzhong , Shi Jade , Loy Clement T. , Amendt Christiane , Wilm Claudia , Zenke Frank T. , Mitchison Timothy J.
Published: April 2023

Supplementary Fig. from Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
Supplementary Figure 3 from Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors
Authors: Tripathi Rakshamani , Samadder Tanmoy , Gupta Sarika , Surolia Avadhesha , Shaha Chandrima
Published: April 2023

Supplementary Figure 3 from Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors
Supplementary Material from Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography
Authors: Woo L.W. Lawrence , Fischer Delphine S. , Sharland Christopher M. , Trusselle Melanie , Foster Paul A. , Chander Surinder K. , Di Fiore Anna , Supuran Claudiu T. , De Simone Giuseppina , Purohit Atul , Reed Michael J. , Potter Barry V.L.
Published: April 2023

Supplementary Material from Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography
Supplementary Table S5 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Authors: Mei Szu-Chieh , Wu Rong-Tsun
Published: April 2023

Supplementary Table S5 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Supplementary Fig. S6 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Authors: Mei Szu-Chieh , Wu Rong-Tsun
Published: April 2023

Supplementary Fig. S6 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Supplementary Data from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Authors: Mei Szu-Chieh , Wu Rong-Tsun
Published: April 2023

Supplementary Data from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Supplementary Data for M S Squires et al from Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
Authors: Squires Matthew S. , Feltell Ruth E. , Wallis Nicola G. , Lewis E. Jonathan , Smith Donna-Michelle , Cross David M. , Lyons John F. , Thompson Neil T.
Published: April 2023

Additional information to provide an insight into the full kinase selectivity profile of AT7519 and full details of its pharmakokinetic parameters
Supplementary Materials and Methods from Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy
Authors: Jeon Yong Hyun , Choi Yun , Yoon Sun Och , Kim Chul Woo , Chung June-Key
Published: April 2023

Supplementary Materials and Methods from Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy
Supplementary Fig. S1 from A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells
Authors: Kim Byung Hak , Yin Chang-Hong , Guo Qianxu , Bach Erika A. , Lee Haeryun , Sandoval Claudio , Jayabose Somasundaram , Ulaczyk-Lesanko Agnieszka , Hall Dennis G. , Baeg Gyeong-Hun
Published: April 2023

Supplementary Fig. S1 from A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells
Supplementary Figure 2 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells
Authors: Chetty Chandramu , Lakka Sajani S. , Bhoopathi Praveen , Gondi Christopher S. , Veeravalli Krishna Kumar , Fassett Daniel , Klopfenstein Jeffrey D. , Dinh Dzung H. , Gujrati Meena , Rao Jasti S.
Published: April 2023

Supplementary Figure 2 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells
Supplementary Figure 1 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells
Authors: Chetty Chandramu , Lakka Sajani S. , Bhoopathi Praveen , Gondi Christopher S. , Veeravalli Krishna Kumar , Fassett Daniel , Klopfenstein Jeffrey D. , Dinh Dzung H. , Gujrati Meena , Rao Jasti S.
Published: April 2023

Supplementary Figure 1 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells
Supplementary Figure Legends from Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells
Authors: García-Morales Pilar , Hernando Eva , Carrasco-García Estefanía , Menéndez-Gutierrez María Piedad , Saceda Miguel , Martínez-Lacaci Isabel
Published: April 2023

Supplementary Figure Legends from Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells
Supplementary Figure Legends from Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
Authors: Guo Wei , Wu Shuhong , Wang Li , Wang Rui-yu , Wei Xiaoli , Liu Jinsong , Fang Bingliang
Published: April 2023

Supplementary Figure Legends from Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
Supplementary Fig. S1 from Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
Authors: Guo Wei , Wu Shuhong , Wang Li , Wang Rui-yu , Wei Xiaoli , Liu Jinsong , Fang Bingliang
Published: April 2023

Supplementary Fig. S1 from Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
RERF Conformational Preferenc from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
Authors: Carriero Maria Vincenza , Longanesi-Cattani Immacolata , Bifulco Katia , Maglio Ornella , Lista Liliana , Barbieri Antonio , Votta Giuseppina , Masucci Maria Teresa , Arra Claudio , Franco Renato , De Rosa Mario , Stoppelli Maria Patrizia , Pavone Vincenzo
Published: April 2023

RERF Conformational Preferenc from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
Dattabase Information from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
Authors: Carriero Maria Vincenza , Longanesi-Cattani Immacolata , Bifulco Katia , Maglio Ornella , Lista Liliana , Barbieri Antonio , Votta Giuseppina , Masucci Maria Teresa , Arra Claudio , Franco Renato , De Rosa Mario , Stoppelli Maria Patrizia , Pavone Vincenzo
Published: April 2023

Dattabase Information from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
Supplementary Fig. S2 from CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model
Authors: Ma Xinrong , Norsworthy Kelly , Kundu Namita , Rodgers William H. , Gimotty Phyllis A. , Goloubeva Olga , Lipsky Michael , Li Yanchun , Holt Dawn , Fulton Amy
Published: April 2023

Supplementary Fig. S2 from CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model
Supplementary Fig. S1 from CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model
Authors: Ma Xinrong , Norsworthy Kelly , Kundu Namita , Rodgers William H. , Gimotty Phyllis A. , Goloubeva Olga , Lipsky Michael , Li Yanchun , Holt Dawn , Fulton Amy
Published: April 2023

Supplementary Fig. S1 from CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model
Supplementary Figure Legends 1-2 from MUC1 oncoprotein is a druggable target in human prostate cancer cells
Authors: Joshi Maya Datt , Ahmad Rehan , Yin Li , Raina Deepak , Rajabi Hasan , Bubley Glenn , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplementary Figure Legends 1-2 from MUC1 oncoprotein is a druggable target in human prostate cancer cells
Supplementary Table S1 from Therapeutic value of glycosaminoglycans in cancer
Authors: Yip George W. , Smollich Martin , Götte Martin
Published: April 2023

Supplementary Table S1 from Therapeutic value of glycosaminoglycans in cancer
Supplementary Figure 2 from Base excision repair of reactive oxygen species–initiated 7,8-dihydro-8-oxo-2′-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs
Authors: Preston Thomas J. , Henderson Jeffrey T. , McCallum Gordon P. , Wells Peter G.
Published: April 2023

Supplementary Figure 2 from Base excision repair of reactive oxygen species–initiated 7,8-dihydro-8-oxo-2′-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs
Supplementary Data from 1,25-Dihydroxyvitamin D3 Enhances the Apoptotic Activity of MDM2 Antagonist Nutlin-3a in Acute Myeloid Leukemia Cells Expressing Wild-type p53
Authors: Thompson Thelma , Andreeff Michael , Studzinski George P. , Vassilev Lyubomir T.
Published: April 2023

Supplementary Data from 1,25-Dihydroxyvitamin D3 Enhances the Apoptotic Activity of MDM2 Antagonist Nutlin-3a in Acute Myeloid Leukemia Cells Expressing Wild-type p53
Supplementary Figure 1 from Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression
Authors: Kaliberova Lyudmila N. , Kusmartsev Sergei A. , Krendelchtchikova Valentina , Stockard Cecil R. , Grizzle William E. , Buchsbaum Donald J. , Kaliberov Sergey A.
Published: April 2023

Supplementary Figure 1 from Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression
Supplementary Table from AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Authors: Byth Kate F. , Thomas Andrew , Hughes Gareth , Forder Cheryl , McGregor Alexandra , Geh Catherine , Oakes Sandra , Green Clive , Walker Mike , Newcombe Nicholas , Green Stephen , Growcott Jim , Barker Andy , Wilkinson Robert W.
Published: April 2023

Supplementary Table from AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Supplemental Data from Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
Authors: Balch Curtis , Yan Pearlly , Craft Teresa , Young Suzanne , Skalnik David G. , Huang Tim H-M. , Nephew Kenneth P.
Published: April 2023

Supplemental Data from Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
Supplementary Fig. S1 from Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay
Authors: Marchand Christophe , Lea Wendy A. , Jadhav Ajit , Dexheimer Thomas S. , Austin Christopher P. , Inglese James , Pommier Yves , Simeonov Anton
Published: April 2023

Supplementary Fig. S1 from Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay
Supplementary Fig. from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy
Authors: Thorne Steve H. , Barak Yoram , Liang Wenchuan , Bachmann Michael H. , Rao Jianghong , Contag Christopher H. , Matin A.
Published: April 2023

Supplementary Fig. from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy
Supplementary Data from Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A
Authors: Gu Yongchuan , Patterson Adam V. , Atwell Graham J. , Chernikova Sophia B. , Brown J. Martin , Thompson Larry H. , Wilson William R.
Published: April 2023

Supplementary Data from Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A
Supplementary Table 2 from Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo
Authors: Vlaming Maria L. H. , van Esch Anita , Pala Zeliha , Wagenaar Els , van de Wetering Koen , van Tellingen Olaf , Schinkel Alfred H.
Published: April 2023

Supplementary Table 2 from Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo
Supplementary Table 1 from Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo
Authors: Vlaming Maria L. H. , van Esch Anita , Pala Zeliha , Wagenaar Els , van de Wetering Koen , van Tellingen Olaf , Schinkel Alfred H.
Published: April 2023

Supplementary Table 1 from Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo
Supplementary Figure 1 from Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo
Authors: Vlaming Maria L. H. , van Esch Anita , Pala Zeliha , Wagenaar Els , van de Wetering Koen , van Tellingen Olaf , Schinkel Alfred H.
Published: April 2023

Supplementary Figure 1 from Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo
Supplementary Fig. S2 from Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins
Authors: Huang Min , Miao Ze-Hong , Zhu Hong , Cai Yu-Jun , Lu Wei , Ding Jian
Published: April 2023

Supplementary Fig. S2 from Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins
Supplementary Table 2 from Molecular Evolutionary Analysis of Cancer Cell Lines
Authors: Zhang Yan , Italia Michael J. , Auger Kurt R. , Halsey Wendy S. , Van Horn Stephanie F. , Sathe Ganesh M. , Magid-Slav Michal , Brown James R. , Holbrook Joanna D.
Published: April 2023

Supplementary Table 2 from Molecular Evolutionary Analysis of Cancer Cell Lines
Supplementary Figure 1 from Molecular Evolutionary Analysis of Cancer Cell Lines
Authors: Zhang Yan , Italia Michael J. , Auger Kurt R. , Halsey Wendy S. , Van Horn Stephanie F. , Sathe Ganesh M. , Magid-Slav Michal , Brown James R. , Holbrook Joanna D.
Published: April 2023

Supplementary Figure 1 from Molecular Evolutionary Analysis of Cancer Cell Lines
Supplementary Data from Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity
Authors: Salerno Erica , Scaglione Brian J. , Coffman Frederick D. , Brown Brian D. , Baccarini Alessia , Fernandes Helen , Marti Gerald , Raveche Elizabeth S.
Published: April 2023

Supplementary Data from Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity
Supplementary Information from Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer
Authors: Sørlie Therese , Perou Charles M. , Fan Cheng , Geisler Stephanie , Aas Turid , Nobel Andrew , Anker Gun , Akslen Lars A. , Botstein David , Børresen-Dale Anne-Lise , Lønning Per Eystein
Published: April 2023

Supplementary Information from Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer
Supplementary Table 1 from Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity
Authors: Gujar Shashi A. , Marcato Paola , Pan Da , Lee Patrick W.K.
Published: April 2023

Supplementary Table 1 from Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity
Supplementary Fig. from Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment
Authors: Burkitt Kyunghee , Chun Sang Y. , Dang Duyen T. , Dang Long H.
Published: April 2023

Supplementary Fig. from Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment
Supplementary Material from Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
Authors: Shangary Sanjeev , Ding Ke , Qiu Su , Nikolovska-Coleska Zaneta , Bauer Joshua A. , Liu Meilan , Wang Guoping , Lu Yipin , McEachern Donna , Bernard Denzil , Bradford Carol R. , Carey Thomas E. , Wang Shaomeng
Published: April 2023

Supplementary Material from Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
Supplementary Table S3 from Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
Authors: Baird Richard D. , Kitzen Jos , Clarke Paul A. , Planting Andre , Reade Sarah , Reid Alison , Welsh Lyndsey , López Lázaro Luis , de las Heras Begona , Judson Ian R. , Kaye Stan B. , Eskens Ferry , Workman Paul , deBono Johann S. , Verweij Jaap
Published: April 2023

Supplementary Table S3 from Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
Supplementary Figure 2 from Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer
Authors: Ohori Hisatsugu , Yamakoshi Hiroyuki , Tomizawa Masaki , Shibuya Masatoshi , Kakudo Yuichi , Takahashi Atsuko , Takahashi Shin , Kato Satoshi , Suzuki Takao , Ishioka Chikashi , Iwabuchi Yoshiharu , Shibata Hiroyuki
Published: April 2023

Supplementary Figure 2 from Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer
Supplementary Figures 1-5 and Legends from The Dynamin Inhibitors MiTMAB and OcTMAB Induce Cytokinesis Failure and Inhibit Cell Proliferation in Human Cancer Cells
Authors: Joshi Sanket , Perera Swetha , Gilbert Jayne , Smith Charlotte M. , Mariana Anna , Gordon Christopher P. , Sakoff Jennette A. , McCluskey Adam , Robinson Phillip J. , Braithwaite Antony W. , Chircop Megan
Published: April 2023

Supplementary Figures 1-5 and Legends from The Dynamin Inhibitors MiTMAB and OcTMAB Induce Cytokinesis Failure and Inhibit Cell Proliferation in Human Cancer Cells
Supplementary Figure 4 from A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Authors: Lam Lloyd T. , Lu Xin , Zhang Haichao , Lesniewski Rick , Rosenberg Saul , Semizarov Dimitri
Published: April 2023

Supplementary Figure 4 from A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Supplementary Tables 1-3 from Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context
Authors: Kuo Wen-Liang , Liu Jing , Mauceri Helena , Vokes Everett E. , Weichselbaum Ralph , Rosner Marsha Rich , Cohen Ezra Eddy Wyssam
Published: April 2023

Supplementary Tables 1-3 from Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context
Supplementary Figures 1-4 from Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma
Authors: Vasudevan Sanjeev A. , Shang Xiaoyi , Chang Shirong , Ge Ningling , Diaz-Miron Jose L. , Russell Heidi V. , Hicks M. John , Ludwig Andrew D. , Wesson Catherine L. , Burlingame Susan M. , Kim Eugene S. , Khan Javed , Yang Jianhua , Nuchtern Jed G.
Published: April 2023

Supplementary Figures 1-4 from Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma
Supplementary Table S1 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
Authors: Shang Yonglei , Mao Yifan , Batson Jennifer , Scales Suzie J. , Phillips Gail , Lackner Mark R. , Totpal Klara , Williams Simon , Yang Jihong , Tang Zhijun , Modrusan Zora , Tan Christine , Liang Wei-Ching , Tsai Siao Ping , Vanderbilt Alexander , Kozuka Kenji , Hoeflich Klaus , Tien Janet , Ross Sarajane , Li Congfen , Lee Sang Hoon , Song An , Wu Yan , Stephan Jean-Philippe , Ashkenazi Avi , Zha Jiping
Published: April 2023

Supplementary Table S1 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
Supplementary Table 1 from MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
Authors: Shimomura Toshiyasu , Hasako Shinichi , Nakatsuru Yoko , Mita Takashi , Ichikawa Koji , Kodera Tsutomu , Sakai Takumi , Nambu Tadahiro , Miyamoto Mayu , Takahashi Ikuko , Miki Satomi , Kawanishi Nobuhiko , Ohkubo Mitsuru , Kotani Hidehito , Iwasawa Yoshikazu
Published: April 2023

Supplementary Table 1 from MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
Supplementary Figure 2 from MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
Authors: Shimomura Toshiyasu , Hasako Shinichi , Nakatsuru Yoko , Mita Takashi , Ichikawa Koji , Kodera Tsutomu , Sakai Takumi , Nambu Tadahiro , Miyamoto Mayu , Takahashi Ikuko , Miki Satomi , Kawanishi Nobuhiko , Ohkubo Mitsuru , Kotani Hidehito , Iwasawa Yoshikazu
Published: April 2023

Supplementary Figure 2 from MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
Supplementary Figure Legends 1-2 from The Mismatch Repair System Modulates Curcumin Sensitivity through Induction of DNA Strand Breaks and Activation of G2-M Checkpoint
Authors: Jiang Zhihua , Jin ShunQian , Yalowich Jack C. , Brown Kevin D. , Rajasekaran Baskaran
Published: April 2023

Supplementary Figure Legends 1-2 from The Mismatch Repair System Modulates Curcumin Sensitivity through Induction of DNA Strand Breaks and Activation of G2-M Checkpoint
Supplementary Figure 1 from The Mismatch Repair System Modulates Curcumin Sensitivity through Induction of DNA Strand Breaks and Activation of G2-M Checkpoint
Authors: Jiang Zhihua , Jin ShunQian , Yalowich Jack C. , Brown Kevin D. , Rajasekaran Baskaran
Published: April 2023

Supplementary Figure 1 from The Mismatch Repair System Modulates Curcumin Sensitivity through Induction of DNA Strand Breaks and Activation of G2-M Checkpoint
Supplementary Data from Chemokine CXC receptor 4–mediated glioma tumor tracking by bone marrow–derived neural progenitor/stem cells
Authors: Xu Qijin , Yuan Xiangpeng , Xu Minlin , McLafferty Fred , Hu Jinwei , Lee Bong Seop , Liu Gentao , Zeng Zhaohui , Black Keith L. , Yu John S.
Published: April 2023

Supplementary Data from Chemokine CXC receptor 4–mediated glioma tumor tracking by bone marrow–derived neural progenitor/stem cells
Supplementary Fig. S1 from Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation
Authors: Jin Jie , Liu Hui , Yang Chunmei , Li Gongchu , Liu Xinyuan , Qian Qijun , Qian Wenbin
Published: April 2023

Supplementary Fig. S1 from Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation
Supplementary Figure Legends from Dihydroartemisinin Induces Apoptosis by a Bak-Dependent Intrinsic Pathway
Authors: Handrick René , Ontikatze Teona , Bauer Kerstin-Daniela , Freier Florian , Rübel Amelie , Dürig Jan , Belka Claus , Jendrossek Verena
Published: April 2023

Supplementary Figure Legends from Dihydroartemisinin Induces Apoptosis by a Bak-Dependent Intrinsic Pathway
Supplementary Table 1, Figure Legends 1-2 from Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival
Authors: Marcu Jahan P. , Christian Rigel T. , Lau Darryl , Zielinski Anne J. , Horowitz Maxx P. , Lee Jasmine , Pakdel Arash , Allison Juanita , Limbad Chandani , Moore Dan H. , Yount Garret L. , Desprez Pierre-Yves , McAllister Sean D.
Published: April 2023

Supplementary Table 1, Figure Legends 1-2 from Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival
Supplementary Figure S4 from Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia
Authors: Banerjee Abhijit G. , Bhattacharyya Indraneel , Vishwanatha Jamboor K.
Published: April 2023

Supplementary Figure S4 from Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia
Supplementary Methods, Figure Legends 1-5, Table Legends 1-4 from Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system
Authors: Foti Carmela , Florean Cristina , Pezzutto Antonio , Roncaglia Paola , Tomasella Andrea , Gustincich Stefano , Brancolini Claudio
Published: April 2023

Supplementary Methods, Figure Legends 1-5, Table Legends 1-4 from Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system
Supplementary Figures 1-5 from Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system
Authors: Foti Carmela , Florean Cristina , Pezzutto Antonio , Roncaglia Paola , Tomasella Andrea , Gustincich Stefano , Brancolini Claudio
Published: April 2023

Supplementary Figures 1-5 from Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system
Supplementary Data from Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice
Authors: Fritz Vanessa , Benfodda Zohra , Rodier Geneviève , Henriquet Corinne , Iborra François , Avancès Christophe , Allory Yves , de la Taille Alexandre , Culine Stéphane , Blancou Hubert , Cristol Jean Paul , Michel Françoise , Sardet Claude , Fajas Lluis
Published: April 2023

Supplementary Data from Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice
Supplementary Figure 1 from Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands
Authors: Wood Tabitha E. , Dalili Shadi , Simpson Craig D. , Sukhai Mahadeo A. , Hurren Rose , Anyiwe Kika , Mao Xinliang , Suarez Saiz Fernando , Gronda Marcela , Eberhard Yanina , MacLean Neil , Ketela Troy , Reed John C. , Moffat Jason , Minden Mark D. , Batey Robert A. , Schimmer Aaron D.
Published: April 2023

Supplementary Figure 1 from Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands
Supplementary Figure 1 from Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma
Authors: Alfano Randall W. , Leppla Stephen H. , Liu Shihui , Bugge Thomas H. , Ortiz Janelle M. , Lairmore Terry C. , Duesbery Nicholas S. , Mitchell Ian C. , Nwariaku Fiemu , Frankel Arthur E.
Published: April 2023

Supplementary Figure 1 from Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma